참고문헌
- Ahlskog, J.E. (2007). I can't get no satisfaction: still no neuroprotection for Parkinson disease. Neurology, 69, 1476-1477 https://doi.org/10.1212/01.wnl.0000277645.60799.0e
- Bain, J., McLauchlan, H., Elliott, M. and Cohen, P. (2003). The specificities of protein kinase inhibitors: an update. Biochem. J., 371, 199-204 https://doi.org/10.1042/BJ20021535
- Barr, R.K. and Bogoyevitch, M.A. (2001). The c-Jun N-terminal protein kinase family of mitogen-activated protein kinases (JNK MAPKs). Int. J. Biochem. Cell Biol., 33, 1047-1063 https://doi.org/10.1016/S1357-2725(01)00093-0
- Barr, R.K., Kendrick, T.S. and Bogoyevitch, M.A. (2002). Identification of the critical features of a small peptide inhibitor of JNK activity. J. Biol. Chem., 277, 10987-10997 https://doi.org/10.1074/jbc.M107565200
- Bennett, B.L., Sasaki, D.T., Murray, B.W., O'Leary, E.C., Sakata, S.T., Xu, W., Leisten, J.C., Motiwala, A., Pierce, S., Satoh, Y., Bhagwat, S.S., Manning, A.M. and Anderson, D.W. (2001). SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. USA, 98, 13681-13686
- Bonny, C., Oberson, A., Negri, S., Sauser, C. and Schorderet, D.F. (2001). Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes, 50, 77-82 https://doi.org/10.2337/diabetes.50.1.77
- Borsello, T. and Bonny, C. (2004). Use of cell-permeable peptides to prevent neuronal degeneration. Trends Mol. Med., 10, 239-244 https://doi.org/10.1016/j.molmed.2004.03.008
- Borsello, T., Clarke, P.G., Hirt, L., Vercelli, A., Repici, M., Schorderet, D.F., Bogousslavsky, J. and Bonny, C. (2003). A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat. Med., 9, 1180-1186
- Borsello, T. and Forloni, G. (2007). JNK signalling: a possible target to prevent neurodegeneration. Curr. Pharm. Des., 13, 1875-1886 https://doi.org/10.2174/138161207780858384
- Carboni, S., Boschert, U., Gaillard, P., Gotteland, J. P., Gillon, J.Y. and Vitte, P.A. (2007). AS601245, a c-Jun NH(2)-terminal kinase (JNK) inhibitor, reduces axon/dendrite damage and cognitive deficits after global cerebral ischaemia in gerbils. Br. J. Pharmacol., 153, 157-163
- Carboni, S., Hiver, A., Szyndralewiez, C., Gaillard, P., Gotteland, J.P. and Vitte, P.A. (2004). AS601245 (1,3-benzothiazol-2-yl (2-[[2-(3-pyridinyl) ethyl] amino]-4 pyrimidinyl) acetonitrile): a c-Jun NH2-terminal protein kinase inhibitor with neuroprotective properties. J. Pharmacol. Exp. Ther., 310, 25-32 https://doi.org/10.1124/jpet.103.064246
- Davis, R.J. (2000). Signal transduction by the JNK group of MAP kinases. Cell, 103, 239-252 https://doi.org/10.1016/S0092-8674(00)00116-1
- Ennis, B.W., Fultz, K.E., Smith, K.A., Westwick, J.K., Zhu, D., Boluro-Ajayi, M., Bilter, G.K. and Stein, B. (2005). Inhibition of tumor growth, angiogenesis, and tumor cell proliferation by a small molecule inhibitor of c-Jun N-terminal kinase. J. Pharmacol. Exp. Ther., 313, 325-332
- Favata, M.F., Horiuchi, K.Y., Manos, E.J., Daulerio, A.J., Stradley, D.A., Feeser, W.S., Van Dyk, D.E., Pitts, W.J., Earl, R.A., Hobbs, F., Copeland, R.A., Magolda, R.L., Scherle, P.A. and Trzaskos, J.M. (1998). Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem., 273, 18623-18632 https://doi.org/10.1074/jbc.273.29.18623
- Ferrandi, C., Ballerio, R., Gaillard, P., Giachetti, C., Carboni, S., Vitte, P.A., Gotteland, J.P. and Cirillo, R. (2004). Inhibition of c-Jun N-terminal kinase decreases cardiomyocyte apoptosis and infarct size after myocardial ischemia and reperfusion in anaesthetized rats. Br. J. Pharmacol., 142, 953-960 https://doi.org/10.1038/sj.bjp.0705873
- Flanc, R.S., Ma, F.Y., Tesch, G.H., Han, Y., Atkins, R.C., Bennett, B.L., Friedman, G.C., Fan, J.H. and Nikolic-Paterson, D.J. (2007). A pathogenic role for JNK signaling in experimental anti-GBM glomerulonephritis. Kidney Int., 72, 698-708 https://doi.org/10.1038/sj.ki.5002404
- Furukawa, M., Ebmeyer, J., Pak, K., Austin, D.A., Melhus, A., Webster, N.J. and Ryan, A.F. (2007). Jun N-terminal protein kinase enhances middle ear mucosal proliferation during bacterial otitis media. Infect. Immun., 75, 2562-2571 https://doi.org/10.1128/IAI.01656-06
- Gaillard, P., Jeanclaude-Etter, I., Ardissone, V., Arkinstall, S., Cambet, Y., Camps, M., Chabert, C., Church, D., Cirillo, R., Gretener, D., Halazy, S., Nichols, A., Szyndralewiez, C., Vitte, P.A. and Gotteland, J.P. (2005). Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase. J. Med. Chem., 48, 4596-607 https://doi.org/10.1021/jm0310986
- Guan, Q.H., Pei, D.S., Zong, Y.Y., Xu, T.L. and Zhang, G.Y. (2006). Neuroprotection against ischemic brain injury by a small peptide inhibitor of c-Jun N-terminal kinase (JNK) via nuclear and non-nuclear pathways. Neuroscience, 139, 609-627 https://doi.org/10.1016/j.neuroscience.2005.11.067
- Han, Z., Boyle, D.L., Chang, L., Bennett, B., Karin, M., Yang, L., Manning, A.M. and Firestein, G.S. (2001). c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J. Clin. Invest., 108, 73-81 https://doi.org/10.1172/JCI12466
- Harper, S.J. and LoGrasso, P. (2001). Signalling for survival and death in neurones: the role of stress-activated kinases, JNK and p38. Cell Signal., 13, 299-310 https://doi.org/10.1016/S0898-6568(01)00148-6
- Hibi, M., Lin, A., Smeal, T., Minden, A. and Karin, M. (1993). Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes. Dev., 7, 2135-2148 https://doi.org/10.1101/gad.7.11.2135
- Hirt, L., Badaut, J., Thevenet, J., Granziera, C., Regli, L., Maurer, F., Bonny, C. and Bogousslavsky, J. (2004). D-JNKI1, a cell-penetrating c-Jun-N-terminal kinase inhibitor, protects against cell death in severe cerebral ischemia. Stroke, 35, 1738-1743 https://doi.org/10.1161/01.STR.0000131480.03994.b1
- Ishii, M., Suzuki, Y., Takeshita, K., Miyao, N., Kudo, H., Hiraoka, R., Nishio, K., Sato, N., Naoki, K., Aoki, T. and Yamaguchi, K. (2004). Inhibition of c-Jun NH2-terminal kinase activity improves ischemia/reperfusion injury in rat lungs. J. Immunol., 172, 2569-2577 https://doi.org/10.4049/jimmunol.172.4.2569
- Kaneko, M., Saito, Y., Saito, H., Matsumoto, T., Matsuda, Y., Vaught, J.L., Dionne, C.A., Angeles, T.S., Glicksman, M.A., Neff, N.T., Rotella, D.P., Kauer, J.C., Mallamo, J.P., Hudkins, R.L. and Murakata, C. (1997). Neurotrophic 3,9- bis[(alkylthio)methyl]-and-bis(alkoxymethyl)-K-252a derivatives. J. Med. Chem., 40, 1863-1869 https://doi.org/10.1021/jm970031d
- Kaneto, H., Nakatani, Y., Miyatsuka, T., Kawamori, D., Matsuoka, T.A., Matsuhisa, M., Kajimoto, Y., Ichijo, H., Yamasaki, Y. and Hori, M. (2004). Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nat. Med., 10, 1128-1132 https://doi.org/10.1038/nm1111
- Kyriakis, J.M. and Avruch, J. (1990). pp54 microtubule-associated protein 2 kinase. A novel serine/threonine protein kinase regulated by phosphorylation and stimulated by poly-L-lysine. J. Biol. Chem., 265, 17355-17363
- Langston, J.W. (1996). The etiology of Parkinson's disease with emphasis on the MPTP story. Neurology, 47, S153-S160 https://doi.org/10.1212/WNL.47.6_Suppl_3.153S
- Lee, J.C., Kumar, S., Griswold, D.E., Underwood, D.C., Votta, B.J. and Adams, J.L. (2000). Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology, 47, 185-201 https://doi.org/10.1016/S0162-3109(00)00206-X
- Ma, F.Y., Flanc, R.S., Tesch, G.H., Han, Y., Atkins, R.C., Bennett, B.L., Friedman, G.C., Fan, J.H. and Nikolic-Paterson, D.J. (2007). A pathogenic role for c-Jun amino-terminal kinase signaling in renal fibrosis and tubular cell apoptosis. J. Am. Soc. Nephrol., 18, 472-484 https://doi.org/10.1681/ASN.2006060604
- Manning, A.M. and Davis, R.J. (2003). Targeting JNK for therapeutic benefit: from junk to gold? Nat. Rev. Drug. Discov., 2, 554-565 https://doi.org/10.1038/nrd1132
- Manning, G., Whyte, D.B., Martinez, R., Hunter, T. and Sudarsanam, S. (2002). The protein kinase complement of the human genome. Science, 298, 1912-1934 https://doi.org/10.1126/science.1075762
- Maroney, A.C., Finn, J.P., Connors, T.J., Durkin, J.T., Angeles, T., Gessner, G., Xu, Z., Meyer, S.L., Savage, M.J., Greene, L.A., Scott, R.W. and Vaught, J.L. (2001). Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family. J. Biol. Chem., 276, 25302-25308 https://doi.org/10.1074/jbc.M011601200
- Maroney, A.C., Glicksman, M.A., Basma, A.N., Walton, K.M., Knight, E., Jr., Murphy, C.A., Bartlett, B.A., Finn, J.P., Angeles, T., Matsuda, Y., Neff, N.T. and Dionne, C.A. (1998). Motoneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signaling pathway. J. Neurosci., 18, 104-111 https://doi.org/10.1523/JNEUROSCI.18-01-00104.1998
- Milano, G., Morel, S., Bonny, C., Samaja, M., von Segesser, L.K., Nicod, P. and Vassalli, G. (2007). A peptide inhibitor of c-Jun NH2-terminal kinase reduces myocardial ischemiareperfusion injury and infarct size in vivo. Am. J. Physiol. Heart. Circ. Physiol., 292, H1828-H1835 https://doi.org/10.1152/ajpheart.01117.2006
- Parkinson Study Group (2007). Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology, 69, 1480-1490 https://doi.org/10.1212/01.wnl.0000277648.63931.c0
- Parkinson Study Group (2004). The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD. Neurology, 62, 330-332 https://doi.org/10.1212/01.WNL.0000103882.56507.20
- Salituro, F.G., Germann, U.A., Wilson, K.P., Bemis, G.W., Fox, T. and Su, M.S. (1999). Inhibitors of p38 MAP kinase: therapeutic intervention in cytokine-mediated diseases. Curr. Med. Chem., 6, 807-823
- Saporito, M.S., Brown, E.M., Miller, M.S. and Carswell, S. (1999). CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine- mediated loss of nigrostriatal dopaminergic neurons In vivo. J. Pharmacol. Exp. Ther., 288, 421-427
- Saporito, M.S., Thomas, B.A. and Scott, R.W. (2000). MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo. J. Neurochem., 75, 1200-1208 https://doi.org/10.1046/j.1471-4159.2000.0751200.x
- Schwarze, S.R., Ho, A., Vocero-Akbani, A. and Dowdy, S.F. (1999). In vivo protein transduction: delivery of a biologically active protein into the mouse. Science, 285, 1569-1572 https://doi.org/10.1126/science.285.5433.1569
- Suckfuell, M., Canis, M., Strieth, S., Scherer, H. and Haisch, A. (2007). Intratympanic treatment of acute acoustic trauma with a cell-permeable JNK ligand: a prospective randomized phase I/II study. Acta Otolaryngol., 127, 938-942 https://doi.org/10.1080/00016480601110212
- Syrkina, O.L., Quinn, D.A., Jung, W., Ouyang, B. and Hales, C.A. (2007). Inhibition of JNK activation prolongs survival after smoke inhalation from fires. Am. J. Physiol. Lung. Cell Mol. Physiol., 292, L984-L991 https://doi.org/10.1152/ajplung.00248.2006
- Uehara, T., Bennett, B., Sakata, S.T., Satoh, Y., Bilter, G.K., Westwick, J.K. and Brenner, D.A. (2005). JNK mediates hepatic ischemia reperfusion injury. J. Hepatol., 42, 850-859 https://doi.org/10.1016/j.jhep.2005.01.030
- Uehara, T., Xi Peng, X., Bennett, B., Satoh, Y., Friedman, G., Currin, R., Brenner, D.A. and Lemasters, J. (2004). c-Jun N-terminal kinase mediates hepatic injury after rat liver transplantation. Transplantation, 78, 324-332
- Waldmeier, P., Bozyczko-Coyne, D., Williams, M. and Vaught, J.L. (2006). Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases. Biochem. Pharmacol., 72, 1197-1206 https://doi.org/10.1016/j.bcp.2006.06.031
- Wang, J., Ruel, J., Ladrech, S., Bonny, C., van de Water, T.R. and Puel, J.L. (2007). Inhibition of the c-Jun N-terminal kinase-mediated mitochondrial cell death pathway restores auditory function in sound-exposed animals. Mol. Pharmacol., 71, 654-666 https://doi.org/10.1124/mol.106.028936
- Wang, J., Van De Water, T.R., Bonny, C., de Ribaupierre, F., Puel, J.L. and Zine, A. (2003). A peptide inhibitor of c-Jun N-terminal kinase protects against both aminoglycoside and acoustic trauma-induced auditory hair cell death and hearing loss. J. Neurosci., 23, 8596-8607 https://doi.org/10.1523/JNEUROSCI.23-24-08596.2003
- Wang, Y., Ji, H.X., Xing, S.H., Pei, D.S. and Guan, Q.H. (2007). SP600125, a selective JNK inhibitor, protects ischemic renal injury via suppressing the extrinsic pathways of apoptosis. Life Sci., 80, 2067-2075 https://doi.org/10.1016/j.lfs.2007.03.010
- Weston, C.R. and Davis, R.J. (2002). The JNK signal transduction pathway. Curr. Opin. Genet. Dev., 12, 14-21 https://doi.org/10.1016/S0959-437X(01)00258-1
- Yang, D.D., Kuan, C.Y., Whitmarsh, A.J., Rincon, M., Zheng, T.S., Davis, R.J., Rakic, P. and Flavell, R.A. (1997). Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature, 389, 865-870 https://doi.org/10.1038/39899